Transient left ventricular dysfunction following chimeric antigen receptor T-cell-mediated encephalopathy: A form of stress cardiomyopathy.
Adam KhorasanchiAmir M AnsariWendy BottinorGary SimmonsAntonio AbbateAmir Ahmed ToorPublished in: EJHaem (2021)
Chimeric antigen receptor (CAR) T-cell therapy represents a new strategy in treating lymphoid malignancies, such as relapsed-refractory diffuse large B-cell lymphoma (DLBCL). Several toxicities including cytokine release syndrome (CRS), neurotoxicity, and cardiovascular toxicity have been linked to CAR T-cell therapy. Transient impairment in left ventricular systolic function is described after CAR-T, however, the mechanism remains poorly understood. This paper reports the clinical presentation and outcome of two patients with relapsed-refractory DLBCL who experienced encephalopathy and CRS following CAR T-cell therapy and developed transient left ventricular dysfunction consistent with stress cardiomyopathy.
Keyphrases
- cell therapy
- diffuse large b cell lymphoma
- left ventricular
- heart failure
- epstein barr virus
- hypertrophic cardiomyopathy
- stem cells
- cardiac resynchronization therapy
- cerebral ischemia
- mesenchymal stem cells
- oxidative stress
- acute myocardial infarction
- aortic stenosis
- mitral valve
- left atrial
- early onset
- blood pressure
- acute lymphoblastic leukemia
- acute myeloid leukemia
- brain injury
- acute coronary syndrome
- coronary artery disease
- atrial fibrillation
- bone marrow
- adverse drug
- percutaneous coronary intervention
- aortic valve